drugset
drugset / Trial / NCT07372625

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625 ↗

Phase 1 Recruiting 14 enrolled PMV Pharmaceuticals, Inc SCRI Development Innovations, LLC · collab
NaSequentialOpen-labelTreatment

Summary

This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Timeline

Start
2026-02-04
Primary completion
2027-03
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral
Subject Midazolam Small molecule 2 mg Oral
Subject Repaglinide Small molecule 0.5 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral
Subject rezatapopt Small molecule 2000 mg Oral

Indications

cancer